3 Branded Formulations Maker, Specialty Chemicals Company and Water Treatment Plants Builder Stocks With a Strong Future Roadmap: Eris Lifesciences, Atul and VA Tech Wabag

Chronic care drug, chemical and water stocks bring together companies with a visible plan for the years ahead. Eris Lifesciences, Atul and VA Tech Wabag cover a branded formulations maker, a specialty chemicals company and a water treatment plants builder.

This list covers three chronic care drug, chemical and water stocks with complete current figures: Eris Lifesciences, Atul and VA Tech Wabag. Every figure comes from the latest reported financials and the 4 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Chronic Care Drug, Chemical and Water Stocks?

Chronic care drug, chemical and water stocks are listed companies that sell branded formulations for chronic care, make life science and performance chemicals, and design, build and operate water and wastewater treatment plants. Their earnings depend on prescriptions, chemical orders and water project spending.

Chronic Care Drug, Chemical and Water Stocks at a Glance

On valuation, Eris Lifesciences and Atul trade at a P/E below the industry P/E, while VA Tech Wabag trades above it, which reflects the growth the market already expects. Readers comparing chronic care drug, chemical and water stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in chronic care drug, chemical and water stocks can use the coming numbers to test whether growth is holding.

Why Do Chronic Care Drug, Chemical and Water Stocks Have a Strong Roadmap in India?

Chronic care drug, chemical and water stocks have a strong roadmap in India because rising chronic care medicine use, wider specialty chemical applications and large water project spending keep widening the market for these companies.

• Branded drugs. Chronic care medicines see steady use.
• Specialty chemicals. Industry needs performance ingredients.
• Water treatment. Cities and factories need clean water.

Why Eris Lifesciences Features Among These Chronic Care Drug, Chemical and Water Stocks

Among the chronic care drug, chemical and water stocks on this list, Eris Lifesciences is an Indian pharmaceutical company with branded formulations in chronic therapies such as cardiac, diabetes and gastro-intestinal care, along with an injectables business.

The company has a return on equity of 15.9%, a debt to equity ratio of 0.60 and a market capitalisation of Rs 15,618 crore. The stock trades at a P/E of 23.5, below the industry P/E of 36.0.

Revenue rose from Rs 1,373 crore in FY22 to Rs 3,137 crore in FY26, a compound annual growth rate of 22.9%. Net profit grew from Rs 406 crore in FY22 to Rs 648 crore in FY26, which works out to a compound annual growth rate of 12.4%. In the June 2026 quarter, revenue grew 12.9% year on year to Rs 876 crore, while net profit rose 14.6% to Rs 143 crore.

Roadmap: Its portfolio expansion, including the addition of branded domestic formulations from other companies and its injectables unit, widens its reach with doctors. Chronic therapy brands bring repeat prescriptions, which supports steady revenue.

What to watch: Check how smoothly acquired brands are integrated and how the injectables unit scales.

Why Atul Features Among These Chronic Care Drug, Chemical and Water Stocks

Among the pharma, chemistry and utility shares on this list, Atul is a Gujarat-based chemical company with life science chemicals for crop protection and pharmaceuticals, and performance and other chemicals that include aromatics, colours and polymers.

Revenue rose from Rs 5,157 crore in FY22 to Rs 6,476 crore in FY26, a compound annual growth rate of 5.9%. Net profit grew from Rs 507 crore in FY23 to Rs 689 crore in FY26, which works out to a compound annual growth rate of 10.8%.

In the June 2026 quarter, revenue grew 25.1% year on year to Rs 1,881 crore, while net profit rose 91.8% to Rs 254 crore. The company has a return on equity of 10.9%, a debt to equity ratio of 0.03 and a market capitalisation of Rs 17,898 crore. The stock trades at a P/E of 22.1, below the industry P/E of 35.1.

Roadmap: The company supplies many industries from a single integrated site and has been adding capacity in higher-value chemicals. A broad product basket across agriculture, pharma and consumer uses spreads demand.

What to watch: Check capacity additions and demand in agrochemical and pharmaceutical intermediates.

Why VA Tech Wabag Features Among These Chronic Care Drug, Chemical and Water Stocks

Among the three companies on this list, VA Tech Wabag designs, builds and operates water and wastewater treatment plants, including desalination and recycling plants, for municipal and industrial customers in India and abroad.

In the June 2026 quarter, revenue grew 26.0% year on year to Rs 939 crore, while net profit rose 36.9% to Rs 90.1 crore. Revenue rose from Rs 3,012 crore in FY22 to Rs 4,038 crore in FY26, a compound annual growth rate of 7.6%.

Net profit grew from Rs 132 crore in FY22 to Rs 370 crore in FY26, which works out to a compound annual growth rate of 29.4%. The company has a return on equity of 14.4%, a debt to equity ratio of 0.09 and a market capitalisation of Rs 11,717 crore. The stock trades at a P/E of 29.7, above the industry P/E of 22.7.

Roadmap: Government missions for drinking water supply and sewage treatment, along with industrial water reuse, feed a long project pipeline. Operation and maintenance contracts add recurring revenue, and international orders widen the customer base.

What to watch: Monitor the order book, the share of operation and maintenance contracts and working capital cycles on large projects.

Eris Lifesciences vs Atul vs VA Tech Wabag on Key Financials

The table below sets the three chronic care drug, chemical and water stocks side by side on revenue, profit and margin, using reported figures.

Eris Lifesciences posts the highest return on equity in this group at 15.9%. Atul has the largest FY26 revenue at Rs 6,476 crore, and Eris Lifesciences shows the fastest revenue growth with a 22.9% compound annual rate. A useful habit with chronic care drug, chemical and water stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several branded formulation, agro intermediate and effluent stocks instead of one name, which keeps a single result from deciding the outcome.

The June 2026 quarter, the latest reported, gives a fresh read on momentum:

Key Risks to Check Before Investing in Chronic Care Drug, Chemical and Water Stocks

Every theme carries risks that deserve a check before any decision. For these chronic care drug, chemical and water stocks, the main points are: Long-term pharma, chemistry and utility shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Regulatory approvals. Plant inspections and approvals can affect supplies.
• Government spending. Public project funding can shift between periods.
• Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter chronic care drug, chemical and water stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Chronic Care Drug, Chemical and Water Stocks

Chronic care drug, chemical and water stocks suit investors who prefer to study business strength before price moves. Eris Lifesciences, Atul and VA Tech Wabag each have a clear plan to grow. Based on the 4 November 2026 close, Eris Lifesciences trades at Rs 1,215, Atul at Rs 5,156.5 and VA Tech Wabag at Rs 1,854.6. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these chronic care drug, chemical and water stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track chronic care drug, chemical and water stocks, set price alerts and get research-backed stock ideas.

What are chronic care drug, chemical and water stocks?

Ans. Chronic care drug, chemical and water stocks are listed companies that sell branded formulations for chronic care, make life science and performance chemicals, and design, build and operate water and wastewater treatment plants. Their earnings depend on prescriptions, chemical orders and water project spending. This list looks at three of them, Eris Lifesciences, Atul and VA Tech Wabag, using reported FY22 to FY26 financials and the 4 November 2026 closing prices.

Which chronic care drug, chemical and water stocks are covered in this list?

Ans. This list covers Eris Lifesciences, Atul and VA Tech Wabag. Based on the 4 November 2026 close, Eris Lifesciences traded at Rs 1,215, Atul at Rs 5,156.5 and VA Tech Wabag at Rs 1,854.6. Their return on equity ranges from 10.9% to 15.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 5.9% to 22.9%.

Why do chronic care drug, chemical and water stocks have a strong future roadmap in India?

Ans. Chronic care drug, chemical and water stocks have a strong roadmap in India because rising chronic care medicine use, wider specialty chemical applications and large water project spending keep widening the market for these companies. The main drivers are as follows. Branded drugs. Chronic care medicines see steady use. Specialty chemicals. Industry needs performance ingredients. Water treatment. Cities and factories need clean water. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Eris Lifesciences performed financially?

Ans. Revenue rose from Rs 1,373 crore in FY22 to Rs 3,137 crore in FY26, a compound annual growth rate of 22.9%. Net profit grew from Rs 406 crore in FY22 to Rs 648 crore in FY26, which works out to a compound annual growth rate of 12.4%. In the June 2026 quarter, revenue grew 12.9% year on year to Rs 876 crore, while net profit rose 14.6% to Rs 143 crore. The company has a return on equity of 15.9%, a debt to equity ratio of 0.60 and a market capitalisation of Rs 15,618 crore. The stock trades at a P/E of 23.5, below the industry P/E of 36.0. Looking ahead, its portfolio expansion, including the addition of branded domestic formulations from other companies and its injectables unit, widens its reach with doctors. Chronic therapy brands bring repeat prescriptions, which supports steady revenue.

How has Atul performed financially?

Ans. Revenue rose from Rs 5,157 crore in FY22 to Rs 6,476 crore in FY26, a compound annual growth rate of 5.9%. Net profit grew from Rs 507 crore in FY23 to Rs 689 crore in FY26, which works out to a compound annual growth rate of 10.8%. In the June 2026 quarter, revenue grew 25.1% year on year to Rs 1,881 crore, while net profit rose 91.8% to Rs 254 crore. The company has a return on equity of 10.9%, a debt to equity ratio of 0.03 and a market capitalisation of Rs 17,898 crore. The stock trades at a P/E of 22.1, below the industry P/E of 35.1. Looking ahead, the company supplies many industries from a single integrated site and has been adding capacity in higher-value chemicals. A broad product basket across agriculture, pharma and consumer uses spreads demand.

How has VA Tech Wabag performed financially?

Ans. Revenue rose from Rs 3,012 crore in FY22 to Rs 4,038 crore in FY26, a compound annual growth rate of 7.6%. Net profit grew from Rs 132 crore in FY22 to Rs 370 crore in FY26, which works out to a compound annual growth rate of 29.4%. In the June 2026 quarter, revenue grew 26.0% year on year to Rs 939 crore, while net profit rose 36.9% to Rs 90.1 crore. The company has a return on equity of 14.4%, a debt to equity ratio of 0.09 and a market capitalisation of Rs 11,717 crore. The stock trades at a P/E of 29.7, above the industry P/E of 22.7. Looking ahead, government missions for drinking water supply and sewage treatment, along with industrial water reuse, feed a long project pipeline. Operation and maintenance contracts add recurring revenue, and international orders widen the customer base.

What risks should investors check before buying chronic care drug, chemical and water stocks?

Ans. Investors should check a few risks before buying chronic care drug, chemical and water stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Government spending. Public project funding can shift between periods. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of chronic care drug, chemical and water stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 4 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.